Plain-English translation of NCT07677410 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
After you receive a catheter-based aortic valve replacement (a procedure called TAVR), your doctors need to prevent blood clots from forming. This trial compares two approaches: taking alone for 12 months, or taking (a stronger blood thinner) for 6 months followed by for another 6 months. The goal is to figure out which plan causes fewer bleeding problems while still preventing dangerous clots and strokes.
Doctors aren't sure which blood-thinning medication plan is best after this type of valve replacement. Some patients may have fewer dangerous bleeds with the simpler approach, while others might be better protected against clots with the stronger initial treatment. This trial will help doctors make better recommendations for future patients.
You likely qualify if…
You likely don't qualify if…
After your valve replacement procedure, you will be randomly assigned to take either alone daily for 12 months, or for 6 months followed by for 6 months. You will have follow-up visits at 30 days, 6 months, and 12 months to check how you are doing, monitor for any bleeding or clot-related problems, and ensure your medication is working well. The study lasts one year total.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
China